Gilead Sciences Inc Stock Price, News & Analysis

Gilead Sciences (NASDAQ:GILD) has launched Choose U™, a global awareness campaign highlighting the experiences of people living with HIV. The initiative, unveiled at the 2025 United States Conference on HIV/AIDS, aims to destigmatize HIV and promote treatment adherence through authentic storytelling.

The campaign emphasizes the U=U (undetectable = untransmittable) movement and features real-world stories from individuals maintaining undetectable viral loads. Currently, only two-thirds of the estimated 40 million people living with HIV globally are virally suppressed. The initial wave includes three individual stories, with more than a dozen additional stories from six countries planned for release through 2026.

Gilead Sciences (NASDAQ:GILD) has broken ground on its new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California. The five-story, 180,000 square foot facility is part of the company's planned $32 billion U.S. investment through 2030, projected to generate over $43 billion in economic value.

The state-of-the-art facility will feature AI-enabled systems, autonomous robotics, and real-time digital monitoring, serving as a hub for innovation in biologics development. This expansion, along with two other facilities under construction, is expected to create over 3,000 direct and indirect jobs and strengthen Gilead's biologics capabilities, a key component of its growth strategy across virology, oncology, and inflammation.

Gilead Sciences (NASDAQ:GILD) has received European Commission (EC) marketing authorization for Yeytuo® (lenacapavir), the first and only twice-yearly injectable HIV prevention treatment in the EU. The authorization covers adults and adolescents weighing at least 35kg who are at increased risk of HIV-1 acquisition.

The approval is supported by two Phase 3 trials: PURPOSE 1 showed zero HIV infections among 2,134 participants, while PURPOSE 2 demonstrated 99.9% effectiveness with only two HIV infections among 2,179 participants. The EC's accelerated decision follows U.S. FDA approval in June and WHO guidelines recommendation in July.

Gilead is executing a global access strategy with regulatory filings in multiple countries and has partnered with The Global Fund to supply lenacapavir for up to two million people in low- and middle-income countries.

Kite, a Gilead (NASDAQ: GILD) subsidiary, has announced the acquisition of Interius BioTherapeutics for $350 million in cash. The acquisition focuses on Interius's innovative in vivo CAR therapeutics platform, which enables CAR T-cell generation directly within patients through a single intravenous infusion.

The platform eliminates the need for traditional cell harvesting, engineering, reinfusion, and preconditioning chemotherapy. The transaction is expected to impact Gilead's 2025 EPS by $0.23-$0.25. Interius's operations will be integrated into Kite's research team, establishing a center of excellence in Philadelphia for developing next-generation in vivo therapies.

Gilead Sciences (Nasdaq: GILD) has announced its participation in four major investor conferences in September 2025. The company's executives will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Annual Global Healthcare Conference (Sept 9), and Baird Global Healthcare Conference (Sept 10).

All presentations will be accessible via live webcasts on Gilead's investor relations website, with replays available for at least 30 days after each event.

Gilead Sciences (NASDAQ:GILD) reported strong Q2 2025 financial results with total revenue increasing 2% to $7.1 billion. Product sales excluding Veklury grew 4% to $6.9 billion, driven by HIV portfolio growth, particularly Biktarvy sales increasing 9% to $3.5 billion.

The company achieved diluted EPS of $1.56 and non-GAAP EPS of $2.01. Key highlights include FDA approval for Yeztugo as the first twice-yearly HIV prevention option and increased 2025 guidance. HIV product sales grew 7% to $5.1 billion, while Trodelvy sales increased 14% to $364 million.

Gilead raised its full-year 2025 guidance, now expecting product sales between $28.3-$28.7 billion and non-GAAP diluted EPS of $7.95-$8.25.

Gilead Sciences (Nasdaq: GILD) received positive CHMP opinions for lenacapavir, its injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) in the European Union. If approved, lenacapavir, to be marketed as Yeytuo®, would become the first and only twice-yearly HIV PrEP option in the EU.

The recommendation is supported by data from the Phase 3 PURPOSE trials, where lenacapavir demonstrated remarkable efficacy: zero HIV infections among 2,134 participants in PURPOSE 1, and only two HIV infections among 2,179 participants in PURPOSE 2, showing superiority over daily oral Truvada.

The CHMP also adopted a positive EU-M4all opinion, which will help facilitate availability in low and lower-middle-income countries. The final European Commission decision is expected later this year, with an additional year of market exclusivity granted for the new indication.

Gilead Sciences (NASDAQ:GILD) has scheduled the release of its Q2 2025 financial results for Thursday, August 7, 2025, after market close. The company's management will host a webcast at 4:30 PM Eastern Time to discuss the quarterly results and provide a business update.

The live webcast will be accessible through the Investors section of Gilead's website and will remain archived for one year. Gilead Sciences is a biopharmaceutical company focused on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer, with operations in over 35 countries.

Gilead Sciences (NASDAQ:GILD) presented new Phase 3 PURPOSE trial data for Yeztugo® (lenacapavir), the first and only FDA-approved twice-yearly HIV prevention injection. The data demonstrated that Yeztugo was effective and well-tolerated across diverse populations, including pregnant women, lactating mothers, adolescents, and young people.

Key findings showed zero HIV infections among 184 pregnant/lactating participants in the Yeztugo group, and strong efficacy in people aged 16-25 years. More than 75% of study participants preferred twice-yearly injectable PrEP over daily oral medication, with over 50% expressing strong preference.

Gilead has submitted regulatory applications in multiple countries and announced a strategic partnership with The Global Fund to supply lenacapavir doses at no profit, aiming to reach up to 2 million people over three years in supported countries.